Description: Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Home Page: www.liminalbiosciences.com
LMNL Technical Analysis
440 Armand-Frappier Boulevard
Laval,
QC
H7V 4B4
Canada
Phone:
450 781 0115
Officers
| Name | Title |
|---|---|
| Mr. Bruce Pritchard BA, CA, FIOD | Chief Exec. Officer |
| Mr. Patrick Sartore | Pres |
| Dr. Gary J. Bridger Ph.D. | Interim Chief Scientific Officer & Non-Independent Director |
| Ms. Marie Iskra L.L.B. | Corp. Sec. & Gen. Counsel |
| Ms. N. Nicole Rusaw C.A., CPA | Chief Financial Officer |
| Shrinal Inamdar | Mang. of Investor Relations & Communications |
| Dr. Steven J. Burton | Pres of Prometic Bioseparations Ltd |
| Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon) | Member of Advisory Committee - Therapeutics |
| Dr. Christopher L. Penney | Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc |
| Dr. Robert G. Rohwer | Member of Scientific Advisory Committee - PRDT |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.6305 |
| Price-to-Book MRQ: | 0.4398 |
| Price-to-Sales TTM: | 32.7585 |
| IPO Date: | 2019-11-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |